Latest articles by Dr Matthew Partridge
-
Middle East conflict: is an all-out war inevitable?
Events have taken an ominous turn in the Middle East after Iran’s attacks on Israel. Will Israel and its allies retaliate, and how bad can it get?
-
Qualcomm could acquire rival Intel – but securing the deal won't be easy
A tie-up between Qualcomm and its semiconductor rival Intel would be a coup. But multiple regulatory and commercial hurdles lie ahead.
-
Google's legal challenges – could it be broken up?
Google is fending off legal challenges from both the EU and the US. But would breaking it up actually work?
-
The US election has witnessed more political violence, just how ugly could it get?
US Election Donald Trump is at the center of the US election yet again, but not for good reason. Will there be a peaceful handover of power in 2025?
US Election -
Apple shares slide amid underwhelming demand for new iPhone
Apple shares fell last week after disappointing demand for the new iPhone 16 Pro. Can Apple depend on AI to give it a boost?
-
Bitcoin miner Riot Platforms bleeds money – what happens now?
Riot Platforms struggles to make a profit and looks absurdly overvalued. Are troubles brewing?
-
Shares in gambling group Entain rise
Shares in Entain rose by 5% after three years of the stock sliding. Is more luck on the cards for the gambling group?
-
Michel Barnier is the new French PM – so, what now?
After a 'stolen election', Michel Barnier, former EU Brexit negotiator has been appointed as France's new prime minister. What does it mean for France?
-
Takeover bid for Japan's 7-Eleven owner from Canadian chain
The Japanese operator of 7-Eleven convenience stores is being wooed by a Canadian peer. But securing a deal won’t be easy
-
The far-right AfD win big in German elections. So what now?
The far-right AfD celebrate a troubling win in Germany. Should politicians treat this warning seriously?
-
Volkswagen mulls closure of German factories
Why is Volkswagen considering the closures and how is the carmaker performing?
-
The battle against heart disease and how to invest in it
Heart disease is soaring due to rising obesity and an ageing population. But new drugs, treatments and diagnostic tools are on the way.
-
M&S recovery has momentum: will it stick?
After years of decline, M&S seems to have turned a corner. But is this just a “dead cat bounce”?
-
Spread betting for beginners: five trading tips
A short-term trading strategy can complement a long-term investment portfolio, but it can be costly for the unwary and reckless
-
Thornbury Castle: a castle stay with pedigree
MoneyWeek Travel Few stately hotels can rival the fascinating history of Thornbury Castle in Gloucestershire – or the opulence, says Matthew Partridge
MoneyWeek Travel -
Is Alpha Group a good buy?
Alpha Group helps clients manage risks such as foreign exchange. After being promoted to the London Stock Exchange, does the stock still rally?
-
Money talks at the Edinburgh Fringe
Matthew Partridge rounds up the best money-themed shows at the Edinburgh Festival.
-
Kellanova shares surge by 16%
Shares in Pringles maker, Kellanova, hiked by 16% – should you buy?
-
Intel stocks slump – can the chipmaker make a comeback?
Semiconductor maker, Intel, missed the boom in the sector thanks to its focus on PCs. Is it too late to catch up with its rivals?
-
Kamala Harris picks Tim Walz for US election run. Will it make a difference?
Kamala Harris has chosen her running mate – does she have a chance against Trump?
-
BP shares bounce back due to shareholder returns – is it good enough?
BP shareholders can expect to pocket a billion-dollar payout due to unexpectedly high profits. But are investors convinced?
-
Diageo announces first sales slump since the pandemic
British drinks company Diageo seems to have lost its spirits after losing almost a tenth of its shares. Do troubles lie ahead for the Guinness maker?
-
Reckitt Benckiser shares hit 10-year low over baby formula fears
Household goods giant Reckitt Benckiser’s shares slumped after rival Abbott's $495 million baby formula lawsuit. Should investors be worried?
-
Vistry sales improve – should you buy into the boom?
Housebuilder Vistry’s unusual business model has fuelled rapid sales growth amid a sluggish private sales market
